Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICING: Isatuximab and Cemiplimab in Relapsed/Refractory NK/T-cell Lymphoid Malignancy
NCT04763616Phase 2Completed
- Start
- Jun 2021
- Primary completion
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of isatuximab and cemiplimab in natural killer/T-cell lymphoma (NKTL) and aggressive NK-cell leukemia (ANKL). Primary endpoint: Complete response rate at 3 years. Started Jun 2021; status: completed.
02
Drugs
isatuximabcemiplimab
03
Conditions
natural killer/T-cell lymphoma (NKTL)aggressive NK-cell leukemia (ANKL)
Beyond the preview
Go deeper on NCT04763616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04763616.